These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Characterization of patients with sporadic colorectal cancer following the new Consensus Molecular Subtypes (CMS)]. Wielandt AM; Villarroel C; Hurtado C; Simian D; Zamorano D; Martínez M; Castro M; Vial MT; Kronberg U; López-Kostner F Rev Med Chil; 2017 Apr; 145(4):419-430. PubMed ID: 28748988 [TBL] [Abstract][Full Text] [Related]
5. Clinical Value of Consensus Molecular Subtypes in Colorectal Cancer: A Systematic Review and Meta-Analysis. Ten Hoorn S; de Back TR; Sommeijer DW; Vermeulen L J Natl Cancer Inst; 2022 Apr; 114(4):503-516. PubMed ID: 34077519 [TBL] [Abstract][Full Text] [Related]
6. Establishment and characterization of cell lines from chromosomal instable colorectal cancer. Maletzki C; Gock M; Randow M; Klar E; Huehns M; Prall F; Linnebacher M World J Gastroenterol; 2015 Jan; 21(1):164-76. PubMed ID: 25574089 [TBL] [Abstract][Full Text] [Related]
7. CMScaller: an R package for consensus molecular subtyping of colorectal cancer pre-clinical models. Eide PW; Bruun J; Lothe RA; Sveen A Sci Rep; 2017 Nov; 7(1):16618. PubMed ID: 29192179 [TBL] [Abstract][Full Text] [Related]
8. The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer. Ros J; Baraibar I; Martini G; Salvà F; Saoudi N; Cuadra-Urteaga JL; Dienstmann R; Tabernero J; Élez E Curr Treat Options Oncol; 2021 Nov; 22(12):113. PubMed ID: 34741675 [TBL] [Abstract][Full Text] [Related]
9. The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications. Soldevilla B; Carretero-Puche C; Gomez-Lopez G; Al-Shahrour F; Riesco MC; Gil-Calderon B; Alvarez-Vallina L; Espinosa-Olarte P; Gomez-Esteves G; Rubio-Cuesta B; Sarmentero J; La Salvia A; Garcia-Carbonero R Eur J Cancer; 2019 Dec; 123():118-129. PubMed ID: 31678770 [TBL] [Abstract][Full Text] [Related]
13. Bioactive Peptides Sensitize Cells to Anticancer Effects of Oxaliplatin in Human Colorectal Cancer Xenografts in Nude Mice. Li X; Xia L; Ouyang X; Suyila Q; Su L; Su X Protein Pept Lett; 2019; 26(7):512-522. PubMed ID: 30950338 [TBL] [Abstract][Full Text] [Related]
14. Chrysophanol exhibits inhibitory activities against colorectal cancer by targeting decorin. Deng M; Xue Y; Xu L; Wang Q; Wei J; Ke X; Wang J; Chen X Cell Biochem Funct; 2020 Jan; 38(1):47-57. PubMed ID: 31710116 [TBL] [Abstract][Full Text] [Related]
15. Classification of patients with metastatic colorectal cancer into consensus molecular subtypes into real-world: A pilot study. González-Montero J; Burotto M; Valenzuela G; Mateluna D; Buen-Abad F; Toro J; Barajas O; Marcelain K World J Clin Oncol; 2023 Oct; 14(10):409-419. PubMed ID: 37970108 [TBL] [Abstract][Full Text] [Related]
16. Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1. Lenz HJ; Argiles G; Yoshino T; Tejpar S; Ciardiello F; Braunger J; Salnikov AV; Gabrielyan O; Schmid R; Höfler J; Kitzing T; Van Cutsem E Clin Colorectal Cancer; 2021 Mar; 20(1):84-95.e8. PubMed ID: 33041226 [TBL] [Abstract][Full Text] [Related]
17. Colorectal Cancer Cell Line Proteomes Are Representative of Primary Tumors and Predict Drug Sensitivity. Wang J; Mouradov D; Wang X; Jorissen RN; Chambers MC; Zimmerman LJ; Vasaikar S; Love CG; Li S; Lowes K; Leuchowius KJ; Jousset H; Weinstock J; Yau C; Mariadason J; Shi Z; Ban Y; Chen X; Coffey RJC; Slebos RJC; Burgess AW; Liebler DC; Zhang B; Sieber OM Gastroenterology; 2017 Oct; 153(4):1082-1095. PubMed ID: 28625833 [TBL] [Abstract][Full Text] [Related]
18. A Clinically Applicable Gene-Expression Classifier Reveals Intrinsic and Extrinsic Contributions to Consensus Molecular Subtypes in Primary and Metastatic Colon Cancer. Piskol R; Huw L; Sergin I; Kljin C; Modrusan Z; Kim D; Kljavin N; Tam R; Patel R; Burton J; Penuel E; Qu X; Koeppen H; Sumiyoshi T; de Sauvage F; Lackner MR; de Sousa E Melo F; Kabbarah O Clin Cancer Res; 2019 Jul; 25(14):4431-4442. PubMed ID: 31004000 [TBL] [Abstract][Full Text] [Related]
19. Pharmacological Inhibition of TFF3 Enhances Sensitivity of CMS4 Colorectal Carcinoma to 5-Fluorouracil through Inhibition of p44/42 MAPK. Chen RM; Chiou YS; Chong QY; Poh HM; Tan TZ; Zhang MY; Ma L; Zhu T; Pandey V; Basappa ; Kumar AP; Lobie PE Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835445 [TBL] [Abstract][Full Text] [Related]
20. Host-microbiota interactions contributing to the heterogeneous tumor microenvironment in colorectal cancer. Li X; Wu D; Li Q; Gu J; Gao W; Zhu X; Yin W; Zhu R; Zhu L; Jiao N Physiol Genomics; 2024 Feb; 56(2):221-234. PubMed ID: 38073489 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]